Method of treating estrogen receptor positive carcinoma with 17 α-dihydroequilin
First Claim
1. A method of treating an estrogen receptor positive carcinoma selected from the group consisting of estrogen receptor positive carcinoma of the breast, uterus, ovary, fallopian tube, cervix, vagina, liver, pituitary, central nervous system, hypothalamus, bone, skin, kidney, urethra, and prostate in a mammal in need thereof which comprises administering to said mammal an effective antineoplastic amount of an active ingredient orally, parenterally, transdermally, topically, rectally, intravaginally, intranasally, or intrabronchially;
- wherein said active ingredient consist essentially of 17α
-dihydroequilin or a sulfate or glucuronide conjugate thereof in substantially purified form.
1 Assignment
0 Petitions
Accused Products
Abstract
This invention provides a method of treating estrogen receptor positive carcinoma in a mammal in need thereof which comprises administering an antineoplastic amount of 17α-dihydroequilin or a mammalian metabolic conjugate thereof orally, parenterally, transdermally, topically, rectally, intravaginally, intranasally, or intrabronchially. As such, the compounds of this invention are useful in treating estrogen receptor positive carcinomas such as carcinomas of the breast, uterus, ovary, fallopian tube, cervix, vagina, liver, pituitary, central nervous system, hypothalamus, bone, skin, kidney, urethra, prostate, and the like.
63 Citations
18 Claims
-
1. A method of treating an estrogen receptor positive carcinoma selected from the group consisting of estrogen receptor positive carcinoma of the breast, uterus, ovary, fallopian tube, cervix, vagina, liver, pituitary, central nervous system, hypothalamus, bone, skin, kidney, urethra, and prostate in a mammal in need thereof which comprises administering to said mammal an effective antineoplastic amount of an active ingredient orally, parenterally, transdermally, topically, rectally, intravaginally, intranasally, or intrabronchially;
- wherein said active ingredient consist essentially of 17α
-dihydroequilin or a sulfate or glucuronide conjugate thereof in substantially purified form. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9)
- wherein said active ingredient consist essentially of 17α
-
10. A method of preventing the growth of an estrogen receptor positive carcinoma, reducing the size of an estrogen receptor positive carcinoma, or eradicating an estrogen receptor positive carcinoma in a mammal bearing an estrogen receptor positive carcinoma which comprises administering to said mammal an effective antineoplastic amount of an active ingredient orally, parenterally, transdermally, topically, rectally, intravaginally, intranasally, or intrabronchially;
- wherein the estrogen receptor positive carcinoma is selected from the group of an estrogen receptor positive carcinoma of the breast, uterus, ovary, fallopian tube, cervix, vagina, liver, pituitary, central nervous system, hypothalamus, bone, skin, kidney, urethra, and prostate; and
wherein said active ingredient consist essentially of 17α
-dihydroequilin or a sulfate or glucuronide conjugate thereof is in substantially purified form. - View Dependent Claims (11, 12, 13, 14, 15, 16, 17, 18)
- wherein the estrogen receptor positive carcinoma is selected from the group of an estrogen receptor positive carcinoma of the breast, uterus, ovary, fallopian tube, cervix, vagina, liver, pituitary, central nervous system, hypothalamus, bone, skin, kidney, urethra, and prostate; and
Specification
-
- Resources
-
Current AssigneeWyeth (Pfizer Inc.)
-
Original AssigneeAmerican Home Products Corporation (Pfizer Inc.)
-
InventorsBex, Frederick J., Dey, Michael S., Corbin, Alan
-
Primary Examiner(s)Goldberg, Jerome D.
-
Application NumberUS07/973,930Time in Patent Office3,367 DaysField of Search514/182US Class Current514/182CPC Class CodesA61K 31/567 substituted in position 17 ...
